GLPwatch
Papers (12034)
Page 90 of 201, ranked by citation count.
- Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide.
- Antidiabetic effects of quercetin and liraglutide combination through modulation of TXNIP/IRS-1/PI3K pathway.
- What is the evidence regarding the safety of new obesity pharmacotherapies.
- Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12).
- Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression.
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
- Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
- Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
- Up and down waves of glycemic control and lower-extremity amputation in diabetes.
- Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
- Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity.
- Insulin and liraglutide attenuate brain pathology in diabetic mice by enhancing the Wnt/β-catenin signaling pathway.
- CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
- Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic β-cell line.
- The GLP-1 receptor is expressed <i>in vivo</i> by human metastatic prostate cancer.
- Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway.
- Folic acid-modified reverse micelle-lipid nanocapsules overcome intestinal barriers and improve the oral delivery of peptides.
- A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.
- Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.
- Liraglutide-induced acute pancreatitis.
- Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla.
- Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
- Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
- Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.
- Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
- The role of incretin receptor agonists in the treatment of obesity.
- Obesity and diabetes: the final frontier.
- Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction.
- Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
- Safety of injectable semaglutide for type 2 diabetes.
- Protective effect of exendin-4 treatment on erectile dysfunction induced by chronic methylglyoxal administration in rats.
- Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.
- A case report of allergy to exenatide.
- PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis.
- The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients.
- GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes.
- Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y<sub>2</sub> Receptor Agonists.
- GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.
- Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.
- Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.
- Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
- GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
- The inhibitory effects of Dulaglutide on cellular senescence against high glucose in human retinal endothelial cells.
- Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway.
- Estimating the lives that could be saved by expanded access to weight-loss drugs.
- GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.
- Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
- Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
- Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.
- Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
- Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
- Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
- Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.
- Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
- Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.
- A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.
- The Effects of Exenatide Microsphere on Serum BGP and ALP Levels in ZDF Rats after Implantation.